4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $31.25 Average PT from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given an average rating of “Moderate Buy” by the ten research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $31.25.

Several equities research analysts have recently issued reports on FDMT shares. Royal Bank Of Canada lifted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Chardan Capital reiterated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. Farther Finance Advisors LLC raised its position in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after buying an additional 2,674 shares during the last quarter. Daiwa Securities Group Inc. raised its position in shares of 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after buying an additional 6,186 shares during the last quarter. Abich Financial Wealth Management LLC bought a new stake in 4D Molecular Therapeutics in the third quarter worth $80,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in 4D Molecular Therapeutics in the fourth quarter worth $77,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Up 0.5%

NASDAQ FDMT traded up $0.05 on Tuesday, reaching $9.50. 38,020 shares of the stock were exchanged, compared to its average volume of 757,459. 4D Molecular Therapeutics has a one year low of $3.00 and a one year high of $12.34. The firm has a market capitalization of $484.98 million, a PE ratio of -3.94 and a beta of 2.94. The company’s 50-day simple moving average is $9.37 and its two-hundred day simple moving average is $9.50.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. The company had revenue of $85.09 million for the quarter, compared to analysts’ expectations of $30.86 million. Sell-side analysts forecast that 4D Molecular Therapeutics will post -3.71 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.